ADC Therapeutics SA cotiza a 1.70 USD y tiene una capitalización bursátil de $217M. En los últimos 12 meses ha facturado $80M con un margen de flujo de caja libre del -173.8%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional a…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.21 | $-0.04 |
| Estimado | $-0.21 | $-0.22 | $-0.20 | $-0.27 |
| Sorpresa | — | — | -5.0% | +85.2% |
| Métrica | ADCT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 92.9% | 57.0% | +35.8% |
| Operating Margin | -149.3% | -38.6% | -110.7% |
| Net Margin | -175.3% | -33.6% | -141.8% |
| FCF Margin | -173.8% | -13.9% | -160.0% |
| ROE | — | -40.4% | — |
| ROA | -44.1% | -32.0% | -12.1% |
| Current Ratio | 4.37 | 2.84 | +1.53 |
| Debt / Equity | — | 0.28 | — |